View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
  1. News
December 29, 2021updated 07 Jan 2022 8:12am

Quidel’s Covid-19 antigen tests can detect Omicron variant

QuickVue At-Home OTC COVID-19 Test and Sofia SARS Antigen FIA can detect the Omicron variant.

Diagnostic healthcare products manufacturer Quidel has confirmed that its antigen tests have the capability to detect the new emerging Covid-19 variants such as Omicron.

Free Report
img

Build resilience in the face of COVID-19 disruption

COVID-19 has already affected our lives forever. The way we work, shop, eat, seek medical advice, and socialize will all be different in the future. Quite how different remains to be seen, but all industries must plan for multiple eventualities. Are you interested in actionable insights on the business challenges induced by the pandemic? GlobalData's cross-sector report analyzes the significance of this major disruptive theme across industry verticals. It provides side-by-side research of alternative datasets to present you with unique quantitative analysis of the effects of COVID-19 and how these differ across sectors. Additionally, it offers qualitative analysis of each sector and analyzes COVID-19’s impact on leading companies. Whatever your company’s imminent strategic plans, the long-lasting impact of COVID-19 must not be overlooked. Find out how to futureproof your business operations – download our report today.
by GlobalData
Enter your details here to receive your free Report.

The company’s Sofia SARS Antigen FIA and QuickVue At-Home OTC COVID-19 Test were found to detect the Omicron variant in the recent testing of live samples from South Africa.

The QuickVue test is designed to detect the nucleocapsid protein antigen from SARS-CoV-2 in people with or without symptoms.

Using self-collected direct anterior nasal swab samples, the test provides results in ten minutes.

The initial findings from RADx laboratory studies showed that the QuickVue antigen tests can detect the Omicron variant with similar performance as with other variants.

The RADx laboratory has conducted the studies using the heat-inactivated Omicron samples. It has also completed the additional testing of the antigen tests using live virus.

Quidel president and CEO Douglas Bryant said: “At Quidel, we continuously monitor the evolution and activity of Covid-19 variants in circulation, and the Omicron variant is no exception.

“Quidel has been, and will continue to be, vigilant in evaluating our assays with both genetic sequencing and real-world virus sample studies to assure customers of our products’ efficacy as the coronavirus evolves.

“Quidel has risen to the challenge and we are proud to be at the forefront of the diagnostic industry’s response to the pandemic.”

Meanwhile, the company has also announced to enhance its weekly Covid-19 antigen tests production to provide affordable Covid-19 testing access to its communities.

Recently, Quidel agreed to acquire Ortho Clinical Diagnostics, for a total consideration of about $6bn.

Related Companies

Free Report
img

Build resilience in the face of COVID-19 disruption

COVID-19 has already affected our lives forever. The way we work, shop, eat, seek medical advice, and socialize will all be different in the future. Quite how different remains to be seen, but all industries must plan for multiple eventualities. Are you interested in actionable insights on the business challenges induced by the pandemic? GlobalData's cross-sector report analyzes the significance of this major disruptive theme across industry verticals. It provides side-by-side research of alternative datasets to present you with unique quantitative analysis of the effects of COVID-19 and how these differ across sectors. Additionally, it offers qualitative analysis of each sector and analyzes COVID-19’s impact on leading companies. Whatever your company’s imminent strategic plans, the long-lasting impact of COVID-19 must not be overlooked. Find out how to futureproof your business operations – download our report today.
by GlobalData
Enter your details here to receive your free Report.

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. The top stories of the day delivered to you every weekday. A weekly roundup of the latest news and analysis, sent every Friday. The medical device industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Medical Device Network